Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Stomach Neoplasms 1Primary Graft Dysfunction 1Liver Neoplasms 1Liver Failure, Acute 1Liver Failure 1Liver Diseases 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 39Radiotherapy 21Carboplatin 21Cetuximab 20Paclitaxel 19Docetaxel 17Radiotherapy, Intensity-Modulated 15pembrolizumab 14Fluorouracil 13Drug Therapy 10Nivolumab 8Radiation 6cemiplimab 5atezolizumab 5Panitumumab 5Oxaliplatin 5Erlotinib Hydrochloride 5Chemoradiotherapy 5Afatinib 5Surgical Procedures, Operative 4durvalumab 3Surveys and Questionnaires 3Methotrexate 3Leucovorin 3Lapatinib 3130-nm albumin-bound paclitaxel 3toripalimab 2palbociclib 2osimertinib 2dacomitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Squamous Cell × halofantrine × Clear all
NCT00490061 2017-03-06

Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy

Stanford University

Phase 2 Terminated
17 enrolled 7 charts
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡